莫西沙星与阿奇霉素治疗生殖支原体感染随机对照试验
FARTHEST 研究为单中心、开放标签、优效性随机对照试验,纳入 358 例经多重 PCR 检测的生殖支原体感染成人,发现莫西沙星 10 天方案治愈率 87.0%,阿奇霉素 6 天方案 61.2%,绝对风险差 25.8%(95%CI 16.5–35.2),支持无耐药检测时莫西沙星作为一线选择。
要点
- 无耐药检测时,莫西沙星微生物学治愈率优于阿奇霉素。
- 阿奇霉素仅在异性恋个体中疗效与莫西沙星相当。
- 多西环素联用未改善治疗结局。
核心结论
- 在无耐药检测条件下,莫西沙星治疗生殖支原体感染的微生物学治愈率显著优于阿奇霉素。
研究设计与样本
- 单中心、开放标签、优效性随机对照试验,纳入 358 例经多重 PCR 检测的生殖支原体感染成人,1:1 随机接受莫西沙星 400 mg 每日一次共 10 天或阿奇霉素 500 mg 每日一次共 6 天。
主要发现
- 意向性分析中,莫西沙星组 87.0% 与阿奇霉素组 61.2% 达到微生物学治愈,绝对风险差 25.8%(95%CI 16.5–35.2)。
- 莫西沙星在 ITT 和 PP 人群中均证实优效性,且在多数亚组中保持优势。
- 阿奇霉素仅在异性恋个体中疗效与莫西沙星相当。
- 多西环素联用未改善治疗结局。
- 两种方案耐受性良好,仅 1 例因不良事件停药。
关键数值与推荐
- 主要终点为治疗完成后 ≥28 天评估的微生物学治愈。
- 莫西沙星组微生物学治愈率 87.0%,阿奇霉素组 61.2%。
- 绝对风险差 25.8%(95%CI 16.5–35.2)。
临床怎么用
- 当生殖支原体耐药检测不可及时,可考虑将莫西沙星作为一线治疗方案。
- 阿奇霉素在异性恋个体中或可考虑使用,但需结合耐药流行情况。
- 多西环素联用未能改善疗效,不建议常规联用。
局限性
- 研究为单中心设计,外推性可能受限。
- 开放标签设计可能引入偏倚。
- 未进行耐药检测,无法评估耐药对疗效的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mycoplasma genitalium (MG) is increasingly characterized by high rates of macrolide and fluoroquinolone resistance. International guidelines recommend resistance-guided therapy; however, access to genotypic testing is limited, and randomized trial evidence is lacking. We assessed the efficacy of moxifloxacin and azithromycin without resistance assays. METHODS: This monocentric, open-label, superiority, randomized controlled trial enrolled adults with MG infection detected by multiplex PCR, randomized 1:1 to receive moxifloxacin 400 mg daily for 10 days or azithromycin 500 mg daily for 6 days. A test of cure was performed ≥28 days after treatment completion. The primary endpoint was microbiological cure in the intention-to-treat (ITT) and per-protocol (PP) populations. Subgroup analyses assessed symptomatic versus asymptomatic infections, doxycycline exposure, re-treatment, and sexual behavior. RESULTS: Among 358 randomized participants, 87.0% of those treated with moxifloxacin and 61.2% of those treated with azithromycin achieved microbiological cure in the ITT analysis (absolute risk difference 25.8%, 95% CI 16.5, 35.2). The superiority of moxifloxacin was confirmed in the ITT and PP populations. Moxifloxacin remained superior across most subgroups, whereas azithromycin showed comparable efficacy only among heterosexual individuals. Doxycycline coadministration did not improve outcomes. Both regimens were well tolerated, with only one case of discontinuation. CONCLUSIONS: Moxifloxacin demonstrated superior efficacy compared to azithromycin for treating MG infection in the absence of resistance testing. These randomized data support the use of moxifloxacin as a first-line option when resistance assays are unavailable and may inform treatment strategies.
引用
- Rossotti R, Baiguera C, Bernasconi DP, et al. A Randomized Clinical Trial to Compare Moxifloxacin Versus Azithromycin for the Treatment of Mycoplasma genitalium: The FARTHEST Study. Clin Infect Dis. 2026. PMID: 42142880. doi:10.1093/cid/ciag317
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。